NAR Cancer

metrics 2024

Pioneering insights for a cancer-free future.

Introduction

NAR Cancer, published by Oxford University Press, is a pioneering open access journal established to advance the rapidly evolving field of cancer research. Since its inception in 2019, this journal has gained substantial recognition, achieving a prestigious Q1 ranking in both Cancer Research and Oncology categories as of 2023. With a focused objective to disseminate high-quality research, reviews, and insights into innovative cancer treatments and diagnostics, NAR Cancer serves as an essential platform for researchers, healthcare professionals, and students alike. The journal is accessible for all since it became open access in 2020, ensuring a global reach and impact. Positioned in the competitive landscape of oncology, with impressive Scopus rankings, it offers a unique opportunity for contributors to share their work with an engaged and interdisciplinary audience. With a commitment to excellence, NAR Cancer is dedicated to driving forward the understanding and management of cancer worldwide.

Metrics 2024

SCIMAGO Journal Rank2.13
Journal Impact Factor3.40
Journal Impact Factor (5 years)4.10
H-Index17
Journal IF Without Self3.40
Eigen Factor0.00
Normal Eigen Factor0.41
Influence1.70
Immediacy Index1.00
Cited Half Life2.60
Citing Half Life7.60
JCI0.72
Total Documents195
WOS Total Citations617
SCIMAGO Total Citations1168
SCIMAGO SELF Citations32
Scopus Journal Rank2.13
Cites / Document (2 Years)3.40
Cites / Document (3 Years)4.18
Cites / Document (4 Years)4.15

Metrics History

Rank 2024

Scopus

Oncology in Medicine
Rank #100/404
Percentile 75.25
Quartile Q1
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #86/230
Percentile 62.61
Quartile Q2

IF (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 138/313
Percentile 56.10
Quartile Q2
ONCOLOGY
Rank 110/322
Percentile 66.00
Quartile Q2

JCI (Web Of Science)

BIOCHEMISTRY & MOLECULAR BIOLOGY
Rank 131/313
Percentile 58.15
Quartile Q2
ONCOLOGY
Rank 139/322
Percentile 56.83
Quartile Q2

Quartile History

Similar Journals

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Connecting Research, Treatment, and Future Directions in Oncology
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

ONCOGENE

Pioneering Genetic Discoveries in Oncology
Publisher: SPRINGERNATUREISSN: 0950-9232Frequency: 50 issues/year

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

CANCER LETTERS

Transforming discoveries into therapeutic realities.
Publisher: ELSEVIER IRELAND LTDISSN: 0304-3835Frequency: 28 issues/year

Cancer Letters, a leading journal published by Elsevier Ireland Ltd, is dedicated to advancing the field of oncology and cancer research. With a rich history that spans from 1975 to 2024, this esteemed journal has established itself as a vital resource within the scientific community, holding a prestigious Q1 status in both Cancer Research and Oncology categories as of 2023. With an impressive ranking of #26/404 in Medicine _ Oncology and #19/230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, Cancer Letters sits in the top percentiles of its field, reflecting its high impact and relevance. Although it does not currently offer open access, the journal remains committed to disseminating paramount research findings, innovative methodologies, and critical reviews that inform and enhance ongoing studies in cancer therapeutics and patient care. Researchers, professionals, and students alike will find invaluable insights into the latest developments and discoveries in cancer research through the pages of Cancer Letters.

GENOME BIOLOGY

Transforming our understanding of genetics and evolution.
Publisher: BMCISSN: 1474-760XFrequency: 1 issue/year

GENOME BIOLOGY is a premier, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genomics, molecular biology, and bioinformatics. Accessible as an Open Access journal since 2000, it aims to disseminate high-quality, cutting-edge research that contributes to our understanding of genome biology's intricate mechanisms. The journal boasts an impressive impact, ranking 8th in Agricultural and Biological Sciences and 9th in Biochemistry, Genetics and Molecular Biology, highlighting its significance among scholars, professionals, and students alike. With a commitment to facilitating the exchange of invaluable scientific knowledge, GENOME BIOLOGY provides an important platform for discussions on evolutionary biology, genetic systems, and cell biology, contributing to the advancement of these dynamic disciplines.

Molecular Oncology

Advancing the Frontiers of Cancer Research.
Publisher: WILEYISSN: 1574-7891Frequency: 10 issues/year

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.

Molecular & Cellular Oncology

Unraveling the complexities of cancer biology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

INTERNATIONAL JOURNAL OF ONCOLOGY

Exploring the frontiers of oncology research.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

EXPERIMENTAL CELL RESEARCH

Shaping the Future of Cell Science
Publisher: ELSEVIER INCISSN: 0014-4827Frequency: 20 issues/year

EXPERIMENTAL CELL RESEARCH is a highly respected journal published by Elsevier Inc, specializing in the dynamic and ever-evolving field of Cell Biology. With an impact factor positioned in the Q2 quartile for 2023, it ranks at the 124th position out of 285 in the Scopus Ranks, indicating a solid reputation among peers in the domains of biochemistry, genetics, and molecular biology. Since its inception in 1950, the journal has contributed significantly to the dissemination of groundbreaking research, providing a platform for studies that explore the nuances of cellular mechanisms, processes, and experimental methodologies. Although the journal currently does not offer open access, its commitment to high-quality, peer-reviewed research continues to attract submissions from leading scientists and scholars across the globe. Researchers, professionals, and students alike will find this journal an invaluable resource for keeping abreast of current developments and innovative breakthroughs in cellular science.

GENE

Illuminating the Path of Genetic Advancements
Publisher: ELSEVIERISSN: 0378-1119Frequency: 48 issues/year

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Illuminating Cellular Processes Through Open Access Research
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.